For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, SpringWorks Therapeutics Inc’s stock clocked out at $42.47, down -3.72% from its previous closing price of $44.11. In other words, the price has decreased by -$3.72 from its previous closing price. On the day, 0.8 million shares were traded. SWTX stock price reached its highest trading level at $44.34 during the session, while it also had its lowest trading level at $42.42.
Ratios:
To gain a deeper understanding of SWTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.37 and its Current Ratio is at 6.41. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on February 05, 2024, initiated with a Buy rating and assigned the stock a target price of $75.
On December 01, 2022, BofA Securities started tracking the stock assigning a Buy rating and target price of $45.
H.C. Wainwright reiterated its Buy rating for the stock on January 19, 2021, while the target price for the stock was revised from $87 to $101.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 16 ’24 when Pichl Daniel sold 15,000 shares for $50.10 per share. The transaction valued at 751,550 led to the insider holds 45,212 shares of the business.
Ashar Bhavesh sold 4,834 shares of SWTX for $238,435 on Feb 05 ’24. The Chief Commercial Officer now owns 58,154 shares after completing the transaction at $49.32 per share. On Feb 02 ’24, another insider, Pichl Daniel, who serves as the Chief People Officer of the company, sold 26,181 shares for $44.32 each. As a result, the insider received 1,160,362 and left with 45,212 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SWTX now has a Market Capitalization of 3145324288 and an Enterprise Value of 2657044992. For the stock, the TTM Price-to-Sale (P/S) ratio is 575.02 while its Price-to-Book (P/B) ratio in mrq is 4.98. Its current Enterprise Value per Revenue stands at 487.8 whereas that against EBITDA is -7.784.
Stock Price History:
Over the past 52 weeks, SWTX has reached a high of $53.92, while it has fallen to a 52-week low of $18.00. The 50-Day Moving Average of the stock is -11.56%, while the 200-Day Moving Average is calculated to be 25.56%.
Shares Statistics:
It appears that SWTX traded 1.11M shares on average per day over the past three months and 648850 shares per day over the past ten days. A total of 73.49M shares are outstanding, with a floating share count of 63.10M. Insiders hold about 14.48% of the company’s shares, while institutions hold 91.49% stake in the company. Shares short for SWTX as of 1711584000 were 10657170 with a Short Ratio of 9.60, compared to 1709164800 on 11125589. Therefore, it implies a Short% of Shares Outstanding of 10657170 and a Short% of Float of 17.43.
Earnings Estimates
The current assessment of SpringWorks Therapeutics Inc (SWTX) involves the perspectives of Seagate Technology Holdings PLC analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $42.47, with high estimates of $73.18 and low estimates of $0.54.
Analysts are recommending an EPS of between $Utilities and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
